| scholarly article | Q13442814 |
| P2093 | author name string | Shan Zeng | |
| Hong Shen | |||
| Junli Ma | |||
| Linda Kapesa | |||
| P2860 | cites work | Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients | Q21261244 |
| Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer | Q26772969 | ||
| Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review | Q26824719 | ||
| Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention | Q26849435 | ||
| Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal | Q27021198 | ||
| Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989 | Q28346792 | ||
| The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification | Q29618627 | ||
| Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer. | Q30724810 | ||
| Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. | Q30785622 | ||
| The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients' survival. | Q33388957 | ||
| Epidemiology of gastric cancer | Q33788193 | ||
| Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas | Q33867088 | ||
| Elimination of gastric cancer from Japan | Q34496573 | ||
| Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial | Q34616772 | ||
| Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. | Q34623247 | ||
| Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) | Q34669648 | ||
| CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients | Q34745772 | ||
| Expression of E-cadherin in gastric carcinoma and its correlation with lymph node micrometastasis | Q35011020 | ||
| Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray | Q35770552 | ||
| Review article: helicobacter pylori and molecular events in precancerous gastric lesions. | Q35845838 | ||
| Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy | Q36496804 | ||
| Familial gastric cancer: detection of a hereditary cause helps to understand its etiology | Q36541982 | ||
| Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes | Q36660380 | ||
| Cdx2 Expression and Intestinal Metaplasia Induced by H. pylori Infection of Gastric Cells Is Regulated by NOD1-Mediated Innate Immune Responses. | Q36705808 | ||
| Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy | Q36957760 | ||
| The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis | Q36996616 | ||
| Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). | Q37491365 | ||
| E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer | Q37812175 | ||
| Role of DNA methylation in the development of diffuse-type gastric cancer | Q37832910 | ||
| Hereditary gastric cancer | Q38050931 | ||
| Familial gastric cancer: genetic susceptibility, pathology, and implications for management | Q38339098 | ||
| Epigenetic alterations in gastric cancer (Review). | Q38495706 | ||
| Targeted therapy for gastric cancer: Current status and future directions (Review). | Q38683236 | ||
| THBS4, a novel stromal molecule of diffuse-type gastric adenocarcinomas, identified by transcriptome-wide expression profiling | Q39519065 | ||
| Current issues in gastric cancer epidemiology | Q40169565 | ||
| HER-2/neu amplification is an independent prognostic factor in gastric cancer. | Q40303656 | ||
| Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines. | Q40629156 | ||
| Diffuse gastric cancer with peritoneal carcinomatosis can mimic Crohn's disease | Q41846243 | ||
| Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients | Q41965292 | ||
| S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis | Q42263964 | ||
| CDH1/E-cadherin germline mutations in early-onset gastric cancer. | Q43146121 | ||
| Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study | Q43264239 | ||
| Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer | Q43788249 | ||
| Searching for E-cadherin gene mutations in early onset diffuse gastric cancer and hereditary diffuse gastric cancer in Korean patients | Q44283452 | ||
| Atypical regenerative changes, dysplasia, and carcinoma in situ in chronic gastritis associated with Helicobacter pylori | Q44309755 | ||
| Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. | Q45031034 | ||
| Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? | Q45210982 | ||
| Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach | Q45279301 | ||
| Clinicopathological Variation of Lauren Classification in Gastric Cancer | Q48071846 | ||
| Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery | Q48667067 | ||
| High microsatellite instability predicts good prognosis in intestinal-type gastric cancers. | Q51503013 | ||
| Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. | Q53128686 | ||
| [Diffuse gastric cancer associated with Ménétrier's disease]. | Q53204044 | ||
| CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions. | Q53259354 | ||
| Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients. | Q54526246 | ||
| HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. | Q54551877 | ||
| [Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma]. | Q54574411 | ||
| Single nucleotide polymorphisms (SNPs) at CDH1 promoter region in familial gastric cancer. | Q54612308 | ||
| Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer | Q57155039 | ||
| Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations | Q58028634 | ||
| E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma | Q59182686 | ||
| [Familial gastric cancer: diagnosis, treatment and periodic surveillance]. | Q62978153 | ||
| Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer | Q74446999 | ||
| CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: Prognostic implications | Q74806677 | ||
| E-cadherin expression as a differentiation marker in gastric cancer | Q78023503 | ||
| Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis | Q79162539 | ||
| [Preventive resection of hereditary diffuse gastric cancer] | Q79388370 | ||
| A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome | Q80564893 | ||
| Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis | Q81168618 | ||
| OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells | Q81461278 | ||
| The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori | Q82586852 | ||
| E-cadherin in gastric carcinomas related to histological prognostic parameters | Q82691852 | ||
| Familial gastric cancer: update for practice management | Q83025575 | ||
| Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation | Q83306000 | ||
| Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer | Q84504572 | ||
| [Association of transcriptional repressor Snail with Lauren classification of gastric cancer] | Q84919484 | ||
| Gastric cancer epidemiology and risk factors | Q85369255 | ||
| Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis | Q85843077 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 2959-2964 | |
| P577 | publication date | 2016-03-16 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Lauren classification and individualized chemotherapy in gastric cancer | |
| P478 | volume | 11 |
| Q92738018 | COL12A1, a novel potential prognostic factor and therapeutic target in gastric cancer |
| Q94500034 | Case report: acute abdominal pain in a 37-year-old patient and the consequences for his family |
| Q54340591 | Comparison of Survival Models for Analyzing Prognostic Factors in Gastric Cancer Patients |
| Q93175115 | Dissection of gastric cancer heterogeneity for precision oncology |
| Q55117181 | Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology. |
| Q98386388 | Distinct prognostic values and antitumor effects of tumor growth factor β1 and its receptors in gastric cancer |
| Q58584387 | Diverse Expression of IL-32 in Diffuse and Intestinal Types of Gastric Cancer |
| Q97681375 | Expression patterns of seven key genes, including β-catenin, Notch1, GATA6, CDX2, miR-34a, miR-181a and miR-93 in gastric cancer |
| Q54967237 | Feasibility of differentiating T3 from T4a gastric cancer in different Lauren classification by determining serosa invasion: Diagnostic performance of high enhanced serosa sign. |
| Q93111311 | In vivo effects of mutant RHOA on tumor formation in an orthotopic inoculation model |
| Q38647893 | Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry |
| Q60301046 | Low periostin expression predicts poor survival in intestinal type gastric cancer patients |
| Q49708044 | Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis. |
| Q92973305 | Multiscale network analysis reveals molecular mechanisms and key regulators of the tumor microenvironment in gastric cancer |
| Q64282336 | Neoplastic Pathogenesis Associated with Cigarette Carcinogens |
| Q54261019 | Next generation sequencing-based emerging trends in molecular biology of gastric cancer. |
| Q90705765 | Prognostic significance of mRNA expression of CASPs in gastric cancer |
| Q37211354 | Rare Presentation of Gastroesophageal Carcinoma with Rectal Metastasis: A Case Report |
| Q92835255 | Regulation of lncRNA PVT1 on miR-125 in metastasis of gastric cancer cells |
| Q90210420 | Resolving gastric cancer aetiology: an update in genetic predisposition |
| Q42160338 | Role of Δ133p53 isoform in NF-κB inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cells |
| Q55075822 | Surgical treatment outcomes of patients with T1-T2 gastric cancer: does the age matter when excellent treatment results are expected? |
| Q100428137 | The changing face of gastric cancer: epidemiologic trends and advances in novel therapies |
| Q57118324 | Tumor-associated macrophages (TAMs) as biomarkers for gastric cancer: A review |
Search more.